Wednesday, 15 Aug 2018

You are here

Predictors of Methotrexate Non-Response

Methotrexate (MTX) is the first line disease-modifying antirheumatic drug (DMARD) used for the treatment of rheumatoid arthritis (RA) as it is the most cost effective first drug, monotherapy drug and the anchor drug upon which most successful combination drug regimens are built around.  As success of this agent is critical to ultimate outcomes, predicting success would be an incredible advantage.

New research from a UK study suggests that nonresponse to oral or subcutaneous MTX was seen in 43% and is predicted by seronegativity, higher disease activity measures and higher anxiety scores.

The Rheumatoid Arthritis Medication Study (RAMS) is a UK multi-centre prospective observational study of patients with RA or undifferentiated polyarthritis, who are started on first line MTX therapy.  MTX non-response at 6 months was based on EULAR response criteria, discontinuation of MTX due to inefficacy or need to start a biologic agent. 

Among 1050 enrolled patients, 43% were classified as non-responders.

Independent predictors of MTX non-response were rheumatoid factor (RF) negativity (OR = 0.62 (0.45, 0.86), higher Health Assessment Questionnaire score (OR=1.64 (1.25, 2.15)), higher tender joint counts (OR=1.06 (1.02, 1.10)), higher anxiety scores (OR=1.07 (1.03, 1.12)) and lower DAS28 scores (OR=0.29 (0.23, 0.39)).

The surprising association with a lower DAS28 score is best explained byt  the method (EULAR) used to calculate a non-response. Thus, patients with a low baseline DAS28 were unable to drop their score by the requisit 0.6 and thus have less of a chance to achieve a response. The AUC for this model was 0.74.

Other sensitivity analyses looked at failing to achieve low disease activity after 6 months of MTX. This was predicted by higher BMI, higher HAQ score, higher TJC28 and higher anxiety score, but not a lower baseline DAS28.

This study is notable by its large size, higher than expected non-response rate (due to dosing?) and the identification of anxiety as a predictive variable in clinical outcome. It is possible that baseline anxiety could be addressed at the start of therapy. 

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Opioid Aversion is Augmenting Spinal Steroid Injections

As physicians turn away from opioids, are they resorting to options that may also be unsafe?

The New York Times reports that some physicians are using the anti-inflammatory drug, Depo-Medrol, for intraspinal injections to manage painful spinal and perispinal disorders.

Company Payments to Rheumatologists, Specialists Linked to Increased ACTH Prescriptions

Despite its exorbitant price tag and paucity of supportive clinical evidence, ACTH (corticotropin) sales have increased in the United States. A recent JAMA article examined its use by specialists and found that those who prescribe ACTH (including rheumatologists, nephrologists, neurologists) received corticotropin-related payments from the products sole manufacturer, Mallinckrod.

Veterans Administration Shuns Marijuana as an Option

Cannabis therapy is legal in 30 states in the US, and soon to be legal in Canada and Great Britian, but the US Veterans Administration continues to reject medical marijuana as a therapeutic option - even in states where it is approved.

Best of 2017: New EULAR Guidelines on Behçet's

At the EULAR 2016 meeting, new EULAR recommendations for the management of Behçet's disease (BD) were presented. These were developed by a multidisciplinary expert committee that reviewed the evidence from the medical literature and developed final set of 9 recommendations:

EULAR 2018 - Day 3 Report

Day 3 highlights include Behcet’s responds to apremilast and that biologics do not differentially affect TKR/THR post-operative infection rates. Be sure to check out today's podcast as well.